FREMONT, Calif, July 03, 2025 (GLOBE NEWSWIRE) -- Actelis Networks, Inc. (NASDAQ: ASNS) ("Actelis" or the "Company"), a market leader in cyber-hardened, rapid deployment networking solutions for IoT and broadband applications, today announced the closing of its previously announced private placement priced at-the-market under Nasdaq rules for the issuance and sale of 1,626,019 shares of its common stock, Series A-3 warrants to purchase up to an aggregate of 1,626,019 shares of common stock and short-term Series A-4 warrants to purchase up to an aggregate of 3,252,038 shares of common stock, at a purchase price of $0.615 per share and associated warrants.
LOS ANGELES, July 3, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Vestis Corporation ("Vestis" or...
LIVINGSTON, N.J., July 3, 2025 /PRNewswire/ -- CoreWeave (Nasdaq: CRWV), the AI Hyperscaler™, today announced it is the first AI cloud provider to deploy the latest...
Ownership of Pension Insurance Corporation Group ("PICG"), ultimate parent company of the specialist insurer of UK defined benefit pension schemes Pension Insurance Corporation ("PIC"),...
SARATOGA, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in its capsule endoscopy solutions, today announced the closing of its initial public offering of 5,500,000 shares of common stock at a public offering price of $5.00 per share. The shares began trading on the Nasdaq Capital Market on July 2, 2025 under the ticker symbol “CV.”
SINGAPORE, July 03, 2025 (GLOBE NEWSWIRE) -- With Bitcoin fluctuating above the $100,000 mark, many analysts predict that the cryptocurrency market will remain in a state of high volatility for the long term. In such a scenario, holding spot positions may struggle to generate short-term profits. As a result, 100x leverage futures trading has become the preferred tool for experienced investors seeking to maximize potential returns in this turbulent market.
MORTON GROVE, Ill., July 3, 2025 /PRNewswire/ -- Lifeway Foods, Inc. (NASDAQ: LWAY) ("Lifeway" or the "Company"), a leading U.S. supplier of Kefir and fermented...
LONDON, July 3, 2025 /PRNewswire/ -- Boldyn Networks (Boldyn), a global leader in private networks and shared communications infrastructure, has been recognised as a Major Player...
LONDON, July 3, 2025 /PRNewswire/ -- Boldyn Networks (Boldyn), a global leader in private networks and shared communications infrastructure, has been recognised as a Major Player...
BOCA RATON, FL, July 03, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company”) the first public company with a treasury strategy built to accumulate and compound Solana (“SOL”), announced today the purchase of 17,760 Solana (“SOL”) at an average purchase price of $153.10 and valued at approximately $2.72 million. Following the transaction, DeFi Development Corp. now holds a total of approximately 640,585 SOL and SOL equivalents, valued at approximately $98.1 million, inclusive of staking rewards.
Vancouver, Canada, July 03, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has received Institutional Review Board (IRB) approval from Tel Aviv Sourasky Medical Center (TASMC) in Tel Aviv, Israel, for its ongoing Phase 1/2a clinical trial evaluating CMND-100, a proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD). This approval will enable patient enrollment at TASMC, a leading clinical site in Israel, prior to commencing this first-in-human trial at the site.